Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metoprolol/tesofensine - Saniona

Next Previous
Drug Profile

Metoprolol/tesofensine - Saniona

Alternative Names: Tesofensine/metoprolol; Tesomet

Latest Information Update: 24 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Saniona
  • Class Antihyperglycaemics; Chlorobenzenes; Heterocyclic bicyclo compounds; Obesity therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Obesity
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Obesity; Prader-Willi syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jan 2023 Efficacy and adverse events data from a phase IIa trial in obesity presented at the 104th Annual Meeting of the Endocrine Society (ENDO-2022)
  • 29 Mar 2022 Saniona suspended a phase II trial in Prader-Willi syndrome (In adults) in Spain, Italy, Sweden, United Kingdom, Australia, New Zealand, USA (PO) due to funding limitations (NCT05198362)
  • 29 Mar 2022 Saniona temporarily paused a phase II trial in Obesity (In adolescents, In adults, In the elderly) in Spain, Italy, United Kingdom, Sweden, Australia, New Zealand, USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top